학술논문

Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease.
Document Type
article
Source
Nature communications. 12(1)
Subject
Intestinal Mucosa
Organoids
Animals
Mice
Inbred C57BL
Mice
Knockout
Humans
Mice
Colitis
Inflammatory Bowel Diseases
Disease Models
Animal
Dextran Sulfate
Treatment Outcome
Likelihood Functions
Cohort Studies
Reproducibility of Results
Gene Expression Regulation
Multigene Family
Artificial Intelligence
AMP-Activated Protein Kinases
Molecular Targeted Therapy
Machine Learning
Inflammatory Bowel Disease
Autoimmune Disease
Digestive Diseases
5.1 Pharmaceuticals
Oral and gastrointestinal
Language
Abstract
Modeling human diseases as networks simplify complex multi-cellular processes, helps understand patterns in noisy data that humans cannot find, and thereby improves precision in prediction. Using Inflammatory Bowel Disease (IBD) as an example, here we outline an unbiased AI-assisted approach for target identification and validation. A network was built in which clusters of genes are connected by directed edges that highlight asymmetric Boolean relationships. Using machine-learning, a path of continuum states was pinpointed, which most effectively predicted disease outcome. This path was enriched in gene-clusters that maintain the integrity of the gut epithelial barrier. We exploit this insight to prioritize one target, choose appropriate pre-clinical murine models for target validation and design patient-derived organoid models. Potential for treatment efficacy is confirmed in patient-derived organoids using multivariate analyses. This AI-assisted approach identifies a first-in-class gut barrier-protective agent in IBD and predicted Phase-III success of candidate agents.